late 1990s
In the late 1990s and early 2000s, drug companies shipped regulatory submissions to FDA and EMA as paper in boxes, according to Scott Cleve.
“back in the late 90s, early aughts, everyone had their picture with the pile of boxes that they were shipping off to FDA or EMA”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:04:06
2000s
Dave Ricks said the Avandia controversy led US regulators to require diabetes drugs to rule out cardiovascular risk before approval, adding years to development.
“And the Avandia one, we know well, we work in diabetes, actually caused a policy change. And the policy change was you must rule out cardiovascular risk prior to market entry.”
Dave Ricks · Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma, 0:22:08
2020
Scott Cleve says the COVID pandemic moved agency resources to vaccines and tests, causing timeline shifts for other products.
“with COVID, we saw obviously there's a pandemic, so that gets raised to the top of the priority list”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:10:59
2020
Scott Cleve says FDA issued several regulations and guidance documents on gene therapy in the year before the interview.
“within the last year, you've seen several regulations and guidance documents from FDA come out about gene therapy, helping set the guardrails of what they expect”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:22:01
2020
Scott Cleve says regulatory inspections often occur at clinical trial sites that are hospitals, which COVID made harder to schedule.
“So oftentimes the inspections will happen at our clinical sites and, you know, at times those were hospitals.”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:25:12
2020
Scott Cleve says written-only agency feedback during COVID meant companies had to ask very specific questions because follow-ups were not possible.
“the questions need to be very specific and targeted to what we want to know, because if we're getting written feedback, there's not an opportunity for a follow-up question”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:24:40
2021
Scott Cleve said bluebird bio planned two FDA filings in the second half of the year and a sickle cell drug filing the following year.
“second half of the year, we have two filings for FDA and then next year our sickle cell drug will be filed.”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:30:25
Undated
Scott Cleve says electronic submissions are gathered, organized, linked for review and sent to the agency through a gateway.
“you gather all of this data and information, you organize it appropriately, you connect it for agency review, and you essentially transmit it through a gateway to the agency.”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:04:35
Undated
Scott Cleve says 80 to 90 percent of the information in regulatory submissions is still sent as electronic paper documents such as PDFs.
“we're still transmitting electronic paper to the agency for 80 or 90 % of the information we want to convey in a submission.”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:08:22
Undated
Scott Cleve cited wearable devices as a new source of real-world evidence that companies can give to health authorities.
“now we have your watch or a wristband or a necklace or patches that can give you information.”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:07:03
Undated
Scott Cleve says submission teams often repackage 90 to 95 percent of the same information for different health authorities.
“Because often we're repackaging 90 % to 95 % of the same information in slightly different ways for different health authorities.”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:18:48
Undated
Scott Cleve believes FDA still leads in setting precedent for drug review data expectations, though EMA, Health Canada and PMDA might disagree.
“in terms of setting precedent in terms of drug review expectations for information and data, I think FDA is still leading the way.”
Scott Cleve · Biopharma Regulatory Requirements with bluebird bio's Scott Cleve, 0:17:36
Undated
A host said Neuralink had received a breakthrough designation for its human brain interface, which they described as a step toward FDA clearance.
“Neuralink got breakthrough designation for their human brain interface. I mean, that's a very big step in allowing the FDA to clear everybody getting an implant.”
Speaker 3 · Sergey Brin, Google Co-Founder | All-In Live from Miami, 0:20:24